Published results from a small study of hematopoietic stem cell transplantation (HSCT) in people with aggressive relapsing-remitting MS not controlled by disease-modifying therapies achieved its primary endpoint with significantly fewer people experiencing MS progression in the group that underwent HSCT. Read more in the Society News.
